Press release content from PR Newswire. The AP news staff was not involved in its creation.
Mission Bio Announces Yan Zhang as New CEO
April 8, 2021 GMT
SAN FRANCISCO, April 8, 2021 /PRNewswire/ Mission Bio, the pioneer in high-throughput single-cell DNA and multi-omics analysis, today announced the appointment of Yan Zhang to the role of CEO. Zhang joins Mission Bio after 10 years at Thermo Fisher Scientific, where she drove above-market growth for multiple business lines, including leading the commercial organization in China for Genetic Sciences and Clinical Next-Generation Sequencing divisions and leading the Reproductive Health and Microarray businesses as General Manager. Zhang succeeds current Mission Bio CEO and co-founder Charlie Silver, who will be moving into an advisor role with the company.
New Study Precisely Characterizes Tumor Heterogeneity in AML Patients Using Mission Bio s Tapestri Platform
Validates multi-omics techniques for measuring therapeutic responses to AML, holding promise for future blood cancer treatments
News provided by
Share this article
Mission Bio, the life sciences company delivering single-cell resolution multi-omics tools to accelerate discoveries and improve time-to-market for new therapeutics, today announced a new study published in
Nature Communications using its Tapestri Platform to perform high-throughput single-cell proteogenomic profiling to precisely characterize tumor heterogeneity in three acute myeloid leukemia (AML) patients across multiple treatment time points.
In conventional AML studies, DNA sequencing and flow cytometry have been used to assess disease genotype and immunophenotype, respectively. However, because a cell s underlying DNA mutation or co-occurring mutations may not robustly predict its immunophenotype,
New Study Precisely Characterizes Tumor Heterogeneity in AML Patients Using Mission Bio s Tapestri Platform prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Key Companies Profiled
$3,188.9 Million
Healthcare experts have found the single-cell multi-omics market to be one of the most rapidly evolving markets, which is predicted to grow at a CAGR of 21.16% during the forecast period, 2020-2025. The market is driven by the need for the development of an advanced solution based on single-cell technology for clinical research in various applications such as cancer, rare disease, cell biology, and synthetic biology, among others.
The market is favored by the development of single-cell technology-based solutions for visualization and analysis of cell heterogeneity, tumor microenvironment, and antibody development. The gradual increase in the prevalence of oncology and rare diseases globally has furthered the single-cell multi-omics market.
Share this article
Share this article
FREMONT, Calif., Feb. 23, 2021 /PRNewswire/ The premium market intelligence report published by BIS Research on the title Global Single-Cell Multi-Omics Market highlights that the market is projected to reach $3.18 billion by 2025. The study also highlights that the market is set to witness a CAGR of 21.16% during the period between 2020 and 2025. The growth is aided by factors including increasing utilization of single-cell RNA sequencing for various cancer research.
The single-cell multi-omics approach enables integrating different molecules and analyzing different types of molecules from a same cell. This helps in accessing multi-faceted information and insights on the characteristics of molecular layers of several individual cells. The information derived is further beneficial in diagnosing and modifying the drugs being developed. Through the advances in single-cell analysis assays, information on the genotypic and phenotypic traits c